CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3461-3464

  Gupta, Suman ^a   Sane, Shraddha A ^a   Shakya, Nishi ^a   Vishwakarma, Preeti ^a   Haq, W ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 2006; IMMUNOSTIMULATING AGENT; LIPOSOME; MILTEFOSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAMSTER; LEISHMANIA DONOVANI; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS;

ANIMALS; CRICETINAE; DRUG COMBINATIONS; FEMALE; LEISHMANIASIS, VISCERAL; MALE; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHORYLCHOLINE; TRYPANOCIDAL AGENTS;

EID: 79959280243     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00137-11     Document Type: Article

References (24)

1. Badaró, R., et al. 1996. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J. Infect. Dis. 173:758-761.
2. Badiee, A., M. R. Jaafari, A. Samiei, D. Soroush, and A. Khamesipour. 2008. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin. Vaccine Immunol. 15:668-674.
3. Bern, C., et al. 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis. 43:917-924.
4. Reference deleted.
5. Bogdon, C. 2008. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell. Microbiol. 10:1221-1234.
6. Bryceson, A. 2001. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 6:928-934.
7. Croft, S., R. Neal, W. Pendergast, and J. Chan. 1987. The activity of alkyl phosphocholines and related derivates against Leishmania donovani. Biochem. Pharmacol. 36:2633-2636.
8. Datta, N., S. Mukherjee, L. Das, and P. K. Das. 2003. Targeting of immunostimulatory DNA cure experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. Eur. J. Immunol. 33:1508-1518.
9. Finney, D. J. 1971. Probit analysis, 3rd ed. Cambridge University Press, Cambridge, United Kingdom.
10. Gupta, S., S. C. Ramesh, and V. M. L. Shrivastava. 2005. Efficacy of picroliv combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis. Acta Trop. 94:41-47.
11. Hartmann, G., B. Noll, W. Shen, C. Schetter, and A. M. Krieg. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164:944-953.
12. Iborra, S., et al. 2008. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect. 10:1133-1141.
13. Jaafari, M. R., et al. 2007. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 25:6107-6117. (Pubitemid 47077540)
14. Jahrsdörfer, B., and G. J. Weiner. 2008. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther. 3:27-32.
15. Kirby, C., and G. Gregoriadis. 1984. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 2:979-984. (Pubitemid 15090594)
16. Krieg, A. M., et al. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
17. Murray, H. W. 1988. Survival of intracellular pathogens within human mononuclear phagocytes. Semin. Hematol. 25:101-111.
18. Sane, S. A., N. Shakya, W. Haq, and S. Gupta. 2010. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis. J. Antimicrob. Chemother. 65:1448-1454.
19. Sundar, S., and M. Chatterjee. 2006. Visceral leishmaniasis - current therapeutic modalities. Indian J. Med. Res. 123:345-352.
20. Sundar, S. 2001. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6:849-854.
21. Utaisincharoen, P., N. Anuntagool, P. Chaisuriya, S. Pichyangkul, and S. Sirisinha. 2002. CpG ODN activates NO and iNOS production in mouse macrophage cell line RAW 264.7. Clin. Exp. Immunol. 128:467-473.
22. Verthelyi, D., and D. M. Klinman. 2003. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol. 109: 64-71.
23. Weeratna, R. D., S. R. Makinen, M. J. McCluskie, and H. L. Davis. 2005. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 23:5263-5270.
24. Zimmermann, S., et al. 1998. Cutting edge: CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160:3627-3630. (Pubitemid 28176060)